Clinical Study of Excimer Laser and Drug Coated Balloon Versus Excimer Laser and Plain Balloon Versus Plain Balloon and Drug Coated Balloon to Treat Femoropopliteal In-stent Restenosis
- Conditions
- In-stent Arterial RestenosisAtherosclerosis of Artery
- Interventions
- Device: Excimer laser and plain balloonDevice: plain balloon and drug coated balloonDevice: Excimer laser and drug coated balloon
- Registration Number
- NCT04365062
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Brief Summary
This is a randomized study comparing Excimer laser and drug coated balloon Versus Excimer laser and plain balloon versus plain balloon and drug coated balloon to Treat femoropopliteal in-stent restenosis
- Detailed Description
This is a randomized study comparing Excimer laser and drug coated balloon Versus Excimer laser and plain balloon versus plain balloon and drug coated balloon to Treat femoropopliteal in-stent restenosis
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 160
Provides written informed consent Willing to comply with follow-up evaluations at specified times Has claudication or rest pain due to peripheral arterial In-stent restenosis Disease located within the femoropopliteal artery Patient has a In-stent restenosis lesion(s) with >50% stenosis documented angiographically Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.
They were excluded if they had one or more of the following: 1. Acute or subacute lower limb ischemia; 2. Severe calcification lesions; 3. Total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated ipsilateral iliac artery stenosis>70%, or the distal runoff artery <1 root; 5. Previously lower extremity intervention or surgical graft artery bypass; 6. Severe renal insufficiency, creatinine level greater than 2.5 mg/dL; 7. The patient's platelet count is less than 100,000/uL, antiplatelet or anticoagulant contraindications to required medications; 8. Patients with immune system diseases or malignant tumours; 9. ongoing active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11. Unwillingness to return for future follow-up visits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Excimer laser and plain balloon Excimer laser and plain balloon Excimer laser and plain balloon group plain balloon and drug coated balloon plain balloon and drug coated balloon plain balloon and drug coated balloon group Intervention: Excimer laser and drug coated balloon Excimer laser and drug coated balloon Intervention: Excimer laser and drug coated balloon group
- Primary Outcome Measures
Name Time Method Primary Patency Rate 12 months Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis \>50% with a peak systolic velocity ratio \>2.4 as measured by Duplex ultrasound.
- Secondary Outcome Measures
Name Time Method Limb Salvage Rate 12 months Limb Salvage is defined as the freedom from secondary major amputation
freedom from clinically-driven TLR 12 months it is defined as freedom from clinically-driven target lesion revascularization
Technical success 1 day Technical success is defined as residual stenosis less than 30% by final angiography and/or a flow-limiting dissection.
Major Adverse Events 12 months Major adverse events included death, index limb ischemia, index limb amputation, and significant embolic events, which were defined as causing end-organ damage.
Trial Locations
- Locations (1)
Gu Yong Quan
🇨🇳Beijing, Beijing, China